Genome-wide sequencing may generate secondary findings (SFs). It is recommended that validated, clinically actionable SFs are reported back to patients/research participants. To explore publics’ perspectives on the best ways to do this, we performed a vignette study among Finnish adults. Our aim was to explore how lay people react to different types of hypothetical genomic SFs. Participants received a hypothetical letter revealing a SF predisposing to a severe but actionable disease - cardiovascular disease (familial hypercholesterolemia, long QT syndrome) or cancer (Lynch syndrome, Li–Fraumeni syndrome). Participants (N=29) wrote down their initial reactions, and discussed (N=23) these in focus groups. Data were analyzed using inductive th...
PurposeApproaches to secondary findings in genome sequencing (GS) are unresolved. In the United King...
The impact of returning secondary results from exome sequencing (ES) on patients/participants is imp...
There is growing impetus to include measures of personal utility, the nonmedical value of informatio...
Genome‐wide sequencing may generate secondary findings (SFs). It is recommended that validated, clin...
Lowered costs of genomic sequencing facilitate analyzing large segments of genetic data. Ethical deb...
Lowered costs of genomic sequencing facilitate analyzing large segments of genetic data. Ethical deb...
With transformative initiatives like the UKâs 100,000 Genomes Project underway, vast amounts of data...
Purpose: In a diagnostic exome sequencing study (the North Carolina Clinical Genomic Evaluation by N...
With large-scale genome sequencing initiatives underway, vast amounts of genomic data are being gene...
IF 2.004 (2017)International audienceWith the development of next generation sequencing, beyond ide...
Incidental or secondary findings (ISFs) are currently among the most debated topics in the domain of...
Exome/genome sequencing (ES/GS) is increasingly becoming routine in clinical genetic diagnosis, yet ...
Introduction: The rapid and growing integration of exome and genome sequencing into clinical genetic...
PURPOSE: Secondary findings (SFs) are present in 1-4% of individuals undergoing genome/exome sequenc...
Purpose: As whole-exome and whole-genome sequencing (WES/WGS) move into routine clinical practice, i...
PurposeApproaches to secondary findings in genome sequencing (GS) are unresolved. In the United King...
The impact of returning secondary results from exome sequencing (ES) on patients/participants is imp...
There is growing impetus to include measures of personal utility, the nonmedical value of informatio...
Genome‐wide sequencing may generate secondary findings (SFs). It is recommended that validated, clin...
Lowered costs of genomic sequencing facilitate analyzing large segments of genetic data. Ethical deb...
Lowered costs of genomic sequencing facilitate analyzing large segments of genetic data. Ethical deb...
With transformative initiatives like the UKâs 100,000 Genomes Project underway, vast amounts of data...
Purpose: In a diagnostic exome sequencing study (the North Carolina Clinical Genomic Evaluation by N...
With large-scale genome sequencing initiatives underway, vast amounts of genomic data are being gene...
IF 2.004 (2017)International audienceWith the development of next generation sequencing, beyond ide...
Incidental or secondary findings (ISFs) are currently among the most debated topics in the domain of...
Exome/genome sequencing (ES/GS) is increasingly becoming routine in clinical genetic diagnosis, yet ...
Introduction: The rapid and growing integration of exome and genome sequencing into clinical genetic...
PURPOSE: Secondary findings (SFs) are present in 1-4% of individuals undergoing genome/exome sequenc...
Purpose: As whole-exome and whole-genome sequencing (WES/WGS) move into routine clinical practice, i...
PurposeApproaches to secondary findings in genome sequencing (GS) are unresolved. In the United King...
The impact of returning secondary results from exome sequencing (ES) on patients/participants is imp...
There is growing impetus to include measures of personal utility, the nonmedical value of informatio...